Antiviral therapy for hepatitis B virus infections: New targets and technical challenges

Journal of Clinical Virology

Volumn 25, Issue 3, 2002, Pages 267-283

  Feld, Jordan ^a,b   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Antiviral agents; Antiviral resistance; Antiviral targets; Hepatitis B virus; Non nucleotide inhibitors

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; COMPLEMENTARY DNA; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE; NUCLEOTIDE;

ANTIMICROBIAL THERAPY; CELL CULTURE; CHROMOSOME; CLINICAL TRIAL; DRUG INDICATION; DRUG RESPONSE; GENE REPLICATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIFE CYCLE; LIVER DISEASE; MUTANT; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; REVIEW; VIRUS ASSEMBLY; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 0036888217     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(02)00107-5     Document Type: Review

References (118)

1. Balsano C., Billet O., Bennoun M., Cavard C., Zider A., Grimber G., Natoli G., et al. Hepatitis B virus X gene product acts as a transactivator in vivo. J. Hepatol. 21:1994;103-109.
2. Bartenschlager R., Junker-Niepmann M., Schaller H. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J. Virol. 64:1990;5324-5332.
3. Bartholomeusz A., Groenen L., Locarnini S.A. Clinical experience with famciclovir against hepatitis B virus and development of resistance. Intervirology. 40:1997;337-342.
4. Block T.M., Jordan R. Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs. Antiviral Chem. Chemother. 12:2002;317-325.
5. Block T.M., Lu X., Platt F.M., Foster G.R., Gerlich W.H., Blumberg B.S., Dwek R.A. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. USA. 91:1994;2235-2239.
6. Blum H.E. Gene therapy of viral hepatitis. Tsuji T., Higashi T., Zeniya M., Meyer zum Buschenfelde K.H., Molecular Biology and Immunology in Hepatology. 8:2002;97-109 Elsevier Science, Freiburg, Germany.
7. Bock C.T., Schranz P., Schroder C.H., Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes. 8:1994;215-229.
8. Bock C.T., Schwinn S., Locarnini S., Fyfe J., Manns M.P., Trautwein C., Zentgraf H. Structural organization of the hepatitis B virus minichromosome. J. Mol. Biol. 307:2001;183-196.
9. Bruss V., Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc. Natl. Acad. Sci. USA. 88:1991;1059-1063.
10. Bruss V., Hagelstein J., Gerhardt E., Galle P.R. Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity. Virology. 218:1996;396-399.
11. Budkowska A., Quan C., Groh F., Bedossa P., Dubreuil P., Bouvet J.P., Pillot J. Hepatitis B virus (HBV) binding factor in human serum: candidate for a soluble form of hepatocyte HBV receptor. J. Virol. 67:1993;4316-4322.
12. Chang L.-J., Hirsch R., Ganem D., Varmus H. Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J. Virol. 64:1990;5553-5558.
13. Chiang P.-W., Jeng K.-S., Hu C.-P., Chang C. Characterisation of a cis element required for packaging and replication of the human hepatitis B virus. Virology. 186:1992;701-711.
14. Chin R., Shaw T., Torresi J., Sozzi V., Trautwein C., Bock T., Manns M., et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45:2001;2495-2501.
15. Civitico G.M., Locarnini S.A. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary duck hepatocyte cultures. Virology. 203:1994;81-89.
16. Dandri M., Burda M.R., Will H., Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology. 32:2000;139-146.
17. Dannaoui E., Trepo C., Zoulim F. Inhibitory effect of penciclovir-triphosphate on duck hepatitis b virus reverse transcription. Antiviral Chem. Chemother. 8:1997;38-46.
18. Das K., Xiong X., Yang H., Westland C.E., Gibbs C.S., Sarafianos S.G., Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75:2001;4771-4779.
19. de Man R., Marcellin P., Habal F., Desmond P., Wright T., Rose T., Jurewicz R., et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis Be antigen-positive hepatitis B. Hepatology. 32:2000;413-417.
20. Dean J., Bowden S., Locarnini S. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Res. 27:1995;171-178.
21. Delaney W.E., Isom H.C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology. 28:1998;1134-1146.
22. Delaney W.E., Miller T.G., Isom H.C. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-,3′-dideoxy-3′thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob. Agents Chemother. 43:1999;2017-2026.
23. Delaney W.E. IV, Locarnini S., Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antiviral Chem. Chemother. 12:2001;1-35.
24. Delaney W.E. IV, Bartholomeusz A., Locarnini S. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin. Invest. Drugs. 11:(2):2002;169-187.
25. Delaney W.E. IV, Edwards R., Colledge D., Shaw T., Furman P., Painter G., Locarnini S. The Phenylopropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 46:(9):2002;3057-3060.
26. Di Bisceglie A.M., McHutchinson J., Rice C.M. New therapeutic strategies for hepatitis C. Hepatology. 35:2002;224-231.
27. Doo E., Liang J.T. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology. 120:2001;1000-1008.
28. Eckhardt S.G., Milich D.R., McLachlan A. Hepatitis B virus core antigen has two nuclear localization sequences in the arginine-rich carboxyl terminus. J. Virol. 65:1991;575-582.
29. Fallows D.A., Goff S.P. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J. Virol. 69:1995;3067-3073.
30. Fourel I., Cullen J.M., Saputelli J., Aldrich C.E., Schaffer P., Averett D.R., Pugh J., et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. 68:1994;8321-8330.
31. Fu L., Cheng Y.-C. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob. Agents Chemother. 44:2000;3402-3407.
32. Ganem D. Assembly of hepadnaviral virions and subviral particles. Curr. Top. Microbiol. Immunol. 168:1991;61-83.
33. Ganem D., Schneider R. Hepadnaviridae: the viruses and their replication. Knipe D.M., Howley P.M., fourth ed. Fields Virology. 2:2001;2923-2970 Lippincott-Raven, Philadelphia.
34. Girones R., Miller R.H. Mutation rate of the hepadnavirus genome. Virology. 170:1989;595-597.
35. Griffith J.D. Chromatin structure deduced from a minichromosome. Science. 187:1975;1202-1203.
36. Hertogs K., Leenders W.P., Depla E., De Bruin W.C., Meheus L., Raymackers J., Moshage H., et al. Endonexin II, present on human liver plasma membranes is a specific binding protein of small hepatitis B virus (HBV) envelope protein. Virology. 197:1993;549-557.
37. Hewish D.R., Burgoyne L.A. Chromatin substructure. The digestion of chromatin DNA at regularly spaced sites by a nuclear deoxyri-bonuclease. Biochem. Biophys. Res. Commun. 52:1973;504-510.
38. Hirsch R.C., Lavine J.E., Chang L.J., Varmus H.E., Ganem D. Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription. Nature. 344:1990;552-555.
39. Hoofnagle J.H. Alpha-interferon therapy of chronic hepatitis B. Current status and recommendations. J. Hepatol. 11:1990;S100-S107.
40. Hu J., Seeger C. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl. Acad. Sci. USA. 93:1996;1060-1064.
41. Hu J., Seeger C. RNA signals that control DNA replication in hepadnaviruses. Semin. Virol. 8:1997;205-211.
42. Hu J., Toft D., Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex, which is incorporated into nucleocapsids. EMBO. 16:1997;59-68.
43. Jeong J.K., Yoon G.S., Ryu W.S. Evidence that the 5′-end cap structure is essential for encapsidation of hepatitis B virus pregenomic RNA. J. Virol. 74:2000;5502-5508.
44. Junker-Niepmann M., Bartenschlager R., Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J. 9:1990;3389-3396.
45. Kann M., Bischof A., Gerlich W.H. In vitro model for the nuclear transport of the hepadnavirus genome. J. Virol. 71:1997;1310-1316.
46. King R.W., Ladner S.K., Miller T.J., Zaifert K., Perni R.B., Conway S.C., Otto M.J. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 42:1998;3179-3186.
47. Klingmuller U., Schaller H. Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J. Virol. 67:1993;7414-7422. issn: 0022-7538x.
48. Knowles B.B., Howe C.C., Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 209:1980;497-499.
49. Kock J., Schlicht H.J. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J. Virol. 67:1993;4867-4874.
50. Koschel M., Thomssen R., Bruss V. Extensive mutagenesis of the hepatitis B virus core gene and mapping of mutations that allow capsid formation. J. Virol. 73:1999;2153-2160.
51. Koschel M., Oed D., Gerelsaikhan T., Thomssen R., Bruss V. Hepatitis B virus core gene mutations which block nucleocapsid envelopment. J. Virol. 74:2000;1-7.
52. Ladner S.K., Otto M.J., Barker C.S., Zaifert K., Wang G.H., Guo J.T., Seeger C., et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1997;1715-1720.
53. Lamivudine Clinical Investigation Group, Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., Brown N., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 27:1998;1670-1677.
54. Lanford R.E., Notvall L., Beames B. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J. Virol. 69:1995;4431-4439.
55. Lavine J., Hirsch R., Ganem D. A system for studying the selective encapsidation of hepadnavirus RNA. J. Virol. 63:1989;4257-4263.
56. Lewin S., Ribeiro R.M., Walter T., Lau G.K.K., Bowden D.S., Locarnini S., Perelson A.S. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology. 34:2001;1012-1120.
57. Lien J.M., Aldrich C.E., Mason W.S. Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis. J. Virol. 57:1986;229-236.
58. Locarnini S., Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV infected patients. J. Hepatol. 30:1999;536-550.
59. Loeb D., Hirsch R., Ganem D. Sequence-independent RNA cleavages generate the primers for plus strand DNA synthesis in hepatitis B viruses: implications for other reverse transcribing elements. EMBO J. 10:1991;3533-3540.
60. Lu X., Mehta A., Dadmarz M., Dwek R., Blumberg B.S., Block T.M. Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited. Proc. Natl. Acad. Sci. USA. 94:1997;2380-2385.
61. Lu X., Lu Y., Geschwindt R., Dwek R.A., Block T.M. Hepatitis B virus MHBs antigen is selectively sensitive to glucosidase-meditated processing in the endoplasmic reticulum. DNA Cell Biol. 20:2001;647-656.
62. Malik A.H., Lee W.M. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann. Intern. Med. 132:2000;723-731.
63. Mehdi H., Kaplan M.J., Anlar F.Y., Yang X., Bayer R., Sutherland K., Peeples M.E. Hepatitis B virus surface antigen binds to apolipoprotein H. J. Virol. 68:1994;2415-2424.
64. Moraleda G., Saputelli J., Aldrich C.E., Averett D., Condreay L., Mason W.S. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. 71:(12):1997;9392-9399.
65. Moriya K., Matsukura M., Kurokawa K., Koike K. In vivo inhibition of hepatitis B virus gene expression by antisense phosporothioate oligonucleotides. Biochem. Biophys. Res. Commun. 218:1996;217-223.
66. Moyer L.A., Mast E.E. Hepatitis B: virology, epidemiology, disease and prevention, an overview of viral hepatitis. Am. J. Prev. Med. 10:(Suppl.):1994;45-55.
67. Nagaya T., Nakamura T., Tokino T., Tsurimoto T., Imai M., Mayumi T., Kamino K., et al. The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev. 1:1987;773-782.
68. Neurath A.R., Kent S.B., Strick N., Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell. 46:1986;429-436.
69. Newbold J.E., Xin H., Tencza M., Sherman G., Dean J., Bowden S., Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minochromosomes. J. Virol. 69:1995;3350-3357.
70. Norder H., Courouce A.M., Magnius L.O. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 198:1994;489-503.
71. Poch O., Sauvaget I., Delarue M., Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. Eur. Mol. Biol. Org. 8:1989;3867-3874.
72. Pollack J.R., Ganem D. An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J. Virol. 67:1993;3254-3263.
73. Pollack J.R., Ganem D. Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis. J. Virol. 68:1994;5579-5587.
74. Pontisso P., Petit M.A., Bankowski M.J., Peeples M.E. Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. J. Virol. 63:1989;1981-1988.
75. Radziwill G., Tucker W., Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J. Virol. 64:1990;613-620.
76. Radziwill G., Zentgraf H., Schaller H., Bosch V. The duck hepatitis B virus DNA polymerase is tightly associated with the viral core structure and unable to switch to an exogenous template. Virology. 163:1988;123-132.
77. Roychoudhury S., Faruqi A.F., Shih C. Pregenomic RNA encapsidation analysis of eleven missense and nonsense polymerase mutants of human hepatitis B virus. J. Virol. 65:1991;3617-3624.
78. Sarafianos SG, Das K, Clark AD, Ding J, Boyer PL, Hughes SH, Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids, Proc Natl Acad Sci USA 1999:96.
79. Schlicht H.J., Kuhn C., Guhr B., Mattaliano R.J., Schaller H. Biochemical and immunological characterization of the duck hepatitis B envelope proteins. J. Virol. 61:1987;2280-2285.
80. Schmitteckert E.M., Schlicht H.-J. Detection of the human hepatitis B virus X-protein in transgenic mice after radioactive labelling at a newly introduced phosphorylation site. J. Gen. Virol. 90:(Pt. 9):1999;2501-2509.
81. Seeger C. The reverse transcriptase of hepatitis B virus. Int. Antiviral News. 2:1994;100-102.
82. Seeger C., Mason W.S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64:2000;51-68.
83. Seifer M., Standring D.N. Recombinant human hepatitis B virus reverse transcriptase is active in the absence of the nucleocapsid or the viral replication origin, DR1. J. Virol. 67:1993;4513-4520.
84. Seifer M., Zhou S., Standring D.N. A micromolar pool of antigenically distinct precursors is required to initiate cooperative assembly of hepatitis B virus capsids in Xenopus oocytes. J. Virol. 67:1993;249-257.
85. Seifer M., Hamatake R., Bifano M., Standring D. Generation of replication competent Hepatitis B virus nucleocapsids in insect cells. J. Virol. 72:1998;2765-2776.
86. Seifer M., Hamatake R.K., Colonno R.J., Standring D.N. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 28:1998;3200-3208.
87. Shaw T., Locarnini S.A. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver. 15:1995;169-184.
88. Shaw T., Locarnini S. Assays for hepatitis B virus DNA- and RNA-dependent DNA polymerase activities. Methods in molecular medicine. Kinchington D., Schinazi R.F., Antiviral and Protocols. 24:2000;87-95 Humana Press, Totowa, NJ, USA. Chapter 8.
89. Shaw T., Mok S.S., Locarnini S.A. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology. 24:1996;996-1002.
90. Shin H.J., Rho H.M. Release of the hepatitis B virus-associated DNA polymerase from the viral particle by the proteolytic cleavage. J. Biol. Chem. 270:1995;11047-11050.
91. Stuyver L., De Gendt S., Van Geyt C., Zoulim F., Fried M., Schinazi R.F., Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J. Gen. Virol. 81:(Pt. 1):2000;67-74.
92. Stuyver L.J., Locarnini S.A., Lok A., Richman D.D., Carman W.F., Dienstag J.L., Schinazi R.F. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 33:2001;751-757.
93. Summers J., Mason W.S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell. 29:1982;403-415.
94. Summers J., Smith P.M., Horwich A.L. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:1990;2819-2824.
95. Summers J., Smith P.M., Huang M.J., Yu M.S. Morphogenetic and regulatory effects of mutations in the envelope proteins of an avian hepadnavirus. J. Virol. 65:1991;1310-1317.
96. Tavis J.E. The replication strategy of the hepadnaviruses. Viral Hepatitis. 2:1996;205-218.
97. Tavis J.E., Ganem D. Expression of functional hepatitis B virus polymerase in yeast reveals it to be the sole viral protein required for correct initiation of reverse transcription. Proc. Natl. Acad. Sci. USA. 90:1993;4107-4111.
98. Tavis J.E., Perri S., Ganem D. Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer. J. Virol. 68:1994;3536-3543.
99. Terradillos O., Billet O., Renard C.-A., Levy R., Molina T., Briand P., Buendia M.A. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene. 14:1997;395-404.
100. Torresi J., Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology. 2:(118):2000;S183-S193.
101. Tuttleman J.S., Pourcel C., Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 47:1986;451-460.
102. Ueda K., Tsurimoto T., Matsubara K. Three envelope proteins of hepatitis B virus: large S, middle S, and major S proteins needed for the formation of Dane particles. J. Virol. 65:1991;3521-3529.
103. Vinograd J., Lebowitz J., Watson R. Early and late helix-coil transitions in closed circular DNA. The number of superhelical turns in polyoma DNA. J. Mol. Biol. 33:1968;173-197.
104. von Weizsacker F., Wieland S., Blum H.E. Identification of two separable modules in the duck hepatitis B virus core protein. J. Virol. 69:1995;2704-2707. issn: 0022-2538x.
105. von Weizsacker F., Wieland S., Blum H. Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein. Hepatology. 24:1996;294-299.
106. von Weizsacker F., Kock J., Wieland S., Offensperger W.B., Blum H.E. Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis. Hepatology. 30:1999;308-315.
107. von Weizsacker F., Kock J., Wieland S., Beck J., Nassal M., Blum H.E. Cis-preferential recruitment of duck hepatitis B virus core protein to the RNA/polymerase preassembly complex. Hepatology. 35:2002;209-216.
108. Wang G.H., Seeger C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell. 71:1992;663-670.
109. Wang G.H., Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 67:1993;6507-6512.
110. Wang G.H., Zoulim F., Leber E.H., Kitson J., Seeger C. Role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses. J. Virol. 68:1994;8437-8442.
111. Weber M., Bronsema V., Bartos H., Bosserhoff A., Bartenschlager R., Schaller H. Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J. Virol. 68:1994;2994-2999.
112. Weber O., Schlemmer K.-H., Hartmann E., Hagelschuer I., Paessens A., Graef E., Deres K., et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. 54:2002;69-78.
113. Xiong X., Flores C., Yang H., Toole J.J., Gibbs C.S. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology. 28:1998;1669-1673.
114. Xiong X., Yang H., Westland C., Zou R., Gibbs C. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology. 31:2000;219-224.
115. Yaginuma K., Shirakata Y., Kobayashi M., Koike K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc. Natl. Acad. Sci. USA. 84:1987;2678-2682.
116. Zoulim F., Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68:1994;6-13.
117. Zoulim F., Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol. 29:1998;151-168.
118. zu Putlitz L., Lanford R.E., Carlson R.I., Notvall L., de la Monte S.M., Wands J.R. Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein. J. Virol. 73:1999;4188-4196.